Clarity: 1st metastatic prostate cancer patient to receive 2 doses of med achieves undetectable PSA level

 Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the first patient ever to be dosed with two cycles of 8GBq of ⁶⁷Cu-SAR-bisPSMA has had a drop in PSA to undetectable levels, undetectable disease using PET and a near complete response to treatment under RECIST. The patient received the first cycle as part of cohort 2 of Clarity's theranostic trial, SECuRE, evaluating ⁶⁴Cu/⁶⁷Cu-SAR-bisPSMA in patients with mCRPC, and a second cycle under the US FDA EAP, as requested by the patient's clinician. The patient experienced a mild dry mouth, altered taste and moderate fatigue, all adverse events resolved themselves.

https://www.biospace.com/article/releases/first-patient-with-metastatic-prostate-cancer-to-receive-2-doses-of-cu-67-sar-bispsma-achieves-undetectable-psa-level/